Joint initiative to focus on expanding early detection and equitable access to care through lung cancer specific AI workflows on Microsoft’s suite of radiology solutions
Bristol-Myers Squibb is one of the premier global companies determined to address oncology research and patient care. It has recently announced the beginning of a strategic collaboration with Microsoft on changing the face of early lung cancer detection through powerful artificial intelligence. This collaboration between the two organizations aspires to provide better access to lifesaving diagnostic services through the implementation of AI-enabled workflows for clinical imaging.
This partnership will use U.S. Food and Drug Administration (FDA)-approved radiology AI algorithms through Microsoft’s Precision Imaging Network. This is a popular solution in which more than 80% of hospitals in the USA are utilizing this technology. This AI-enabled system can analyze X-ray and CT scans to aid in radiology imaging and detect any abnormalities in the lungs.
Lung cancer remains one of the leading causes of mortality due to cancer in the United States and is projected to claim at least 125,000 and 227,000 cases annually. Medical underserved patients, as well as rural populations, show higher mortality rates and poor post-screening care practice rates, which this partnership helps to address.
To improve patient tracking and follow-up, the initiative will also incorporate workflow management tools designed to guide individuals with incidental lung findings through the proper care continuum.
Also Read: Intuitive.ai & Matilda Cloud Forge Strategic Alliance to Drive Secure, Compliant AI and Cloud Modernization in Life Sciences
Statements from Leadership
“By combining Microsoft’s highly scalable radiology solutions with BMS’ deep expertise in oncology and drug delivery, we’ve envisioned a unique AI-enabled workflow that helps clinicians quickly and accurately identify patients with Non-Small Cell Lung Cancer (NSCLC) and guide them to optimal care pathways and precision therapies,” said Dr. Alexandra Goncalves, Vice President and Head of Digital Health, Bristol Myers Squibb. “An integrated, AI-powered platform that streamlines patient flow can significantly improve operational efficiency and patient outcomes.”
Expanding care access to underserved populations is a core objective of the collaboration. “This new Microsoft collaboration reflects our commitment to breaking down barriers and addressing healthcare challenges,” said Andrew Whitehead, Vice President and Head of Population Health, Bristol Myers Squibb. “At BMS, health equity is not a standalone initiative it is embedded in everything we do. By deploying this solution and bringing advanced AI tools to the front lines, together we will help to address health disparities in lung cancer.”
Looking at the technology’s clinical impact, Peter Durlach, Corporate Vice President and Chief Strategy Officer, Microsoft Health and Life Sciences, stated: “With Microsoft’s AI-powered radiology technology platform widely deployed within healthcare delivery organizations across the country and operating behind the scenes, clinicians can more easily identify patients who may be showing early signs of cancer often before they are aware of any symptoms and help guide them into the appropriate care pathway sooner. This is a clear win for both patients and providers and aligns with Microsoft’s goals to utilize technology to unlock insights, increase efficiencies, and improve patient care.”
